Lenzetto

Estradiol, the active ingredient in Lenzetto, is a estrogen presented as a 0.025 mg/24h transdermal patch for transdermal use. It treats moderate to severe vasomotor symptoms of menopause, helps prevent osteoporosis in postmenopausal women, and addresses estrogen deficiency due to hypogonadism.

GNH USA supplies Lenzetto as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto (estradiol) is used in hormone replacement therapy to manage estrogen‑dependent conditions.

- Menopausal vasomotor symptoms: relief of moderate to severe hot flashes and night sweats. - Postmenopausal osteoporosis: prevention of bone loss and reduction of fracture risk. - Hypogonadism‑related estrogen deficiency: restoration of estrogen levels in women with hypogonadism.

Adverse reactions to Lenzetto may vary in frequency and severity.

Common Side Effects: - Skin irritation at application site: redness, itching or rash. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Breast tenderness: mild swelling or soreness.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Stroke or myocardial infarction: increased risk of cardiovascular events. - Endometrial hyperplasia or carcinoma: abnormal uterine bleeding.

Before prescribing Lenzetto, clinicians should consider several precautionary measures.

- Assess cardiovascular risk: evaluate history of thromboembolic disease or stroke. - Review personal or family history of hormone‑sensitive cancers: breast, endometrial, ovarian. - Monitor liver function: estradiol is metabolized hepatically. - Evaluate lipid profile: estrogen therapy may affect cholesterol levels. - Counsel on smoking status: smoking increases thrombotic risk. - Store at room temperature: keep patch in original packaging, protect from moisture and direct sunlight.

Lenzetto can interact with other medications, altering its efficacy or safety.

Major Interactions (Avoid): - Combined oral contraceptives or hormone therapy: increased risk of thromboembolism. - Anticoagulants (warfarin, direct oral anticoagulants): enhanced anticoagulant effect, monitor INR. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced estradiol plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible alteration of blood pressure control. - Antidiabetic agents: estrogen may affect glucose metabolism. - SSRIs and SNRIs: may increase risk of hyponatremia.